CA3251753A1 — Pre-targeting
Assigned to Precirix NV · Expires 2023-11-09 · 3y expired
What this patent protects
The present invention relates to the field of VHHs that may be used in pre-targeting combinations comprising the VHH and a labelled compound. Depending on the application, the labelled compound may comprise a radionuclide. The pre-targeting combinations are preferably for use in …
USPTO Abstract
The present invention relates to the field of VHHs that may be used in pre-targeting combinations comprising the VHH and a labelled compound. Depending on the application, the labelled compound may comprise a radionuclide. The pre-targeting combinations are preferably for use in the treatment and/or diagnosis of a cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.